Affibody Medical Investor Relations
Categories:
Navigation:
Non-Regulatory
December 23, 2022
Affibody signs €20 million loan agreement with the EIB to finance the development of next generation’s biopharmaceuticals against cancer and inflammatory diseases
Solna, Sweden, December 23, 2022. Affibody Medical AB (“Affibody”) today announced that the European Investment Bank, EIB, backed by the InvestEU programme, has provided a €20 million venture debt...
Read more
